Isabelle Bence‐Bruckler

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

Neil L. Berinstein, A.J. Grillo-López, Christine A. White et al. · Annals of Oncology · 1998 · 523 citations · Full text

Medicine, Hematology, Oncology +15

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Martin Dreyling, Wojciech Jurczak, Mats Jerkeman et al. · The Lancet · 2015 · 462 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial

Harold Atkins, Marjorie A. Bowman, David Allan et al. · The Lancet · 2016 · 322 citations

Life Sciences, Hematology, Immunology +13

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Magdalena Klánová, Laurie H. Sehn, Isabelle Bence‐Bruckler et al. · Blood · 2019 · 129 citations · Full text

Medicine, Neurology, Oncology +11